CADL Latest Press Releases

-- November 2, 2026 --

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:05 PM

-- October 29, 2026 --

Candel Therapeutics Announces Late-Breaking Abstract Accepted for Poster Presentation at the SITC 2026 Annual Meeting, Featuring Aglatimagene Besadenovec Data in Localized Prostate Cancer Globe Newswire 9:00 AM

-- October 27, 2026 --

Candel Therapeutics to Present at November Investor Conferences Globe Newswire 8:05 AM

-- October 22, 2026 --

Candel Therapeutics Appoints Maria Ostrovsky as General Counsel Globe Newswire 8:05 AM

-- October 2, 2026 --

Candel Therapeutics to Present at the SITC 2026 Annual Meeting Globe Newswire 9:00 AM

-- October 1, 2026 --

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:05 PM

Candel Therapeutics Announces Publication of Phase 2a Trial Data that Demonstrated Prolonged Survival after Systemic Immune Reactivation by Aglatimagene Besadenovec plus Valacyclovir in Patients with Unresectable Stage III/IV NSCLC with an Inadequate Response to ICI Globe Newswire 8:05 AM

-- September 30, 2026 --

Candel Therapeutics Announces Integrated Clinical and Biomarker Data That Showed Durable Local and Systemic Immune Activation after Aglatimagene Besadenovec in Intermediate-Risk Localized Prostate Cancer Globe Newswire 8:30 AM

Candel Therapeutics Announces New Data Showing Sustained Immune Remodeling More Than Two Years After Aglatimagene Besadenovec Treatment in Localized Prostate Cancer at ASTRO 2026 Globe Newswire 8:05 AM

-- September 10, 2026 --

Candel Therapeutics Appoints Martine Zimmermann, PharmD, to its Board of Directors Globe Newswire 8:05 AM

-- September 1, 2026 --

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:05 PM

-- August 26, 2026 --

Candel Therapeutics to Present at September Investor Conferences Globe Newswire 8:05 AM

-- August 13, 2026 --

Candel Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights Globe Newswire 8:05 AM

-- August 3, 2026 --

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:05 PM

Candel Therapeutics to Present Extended Data from Phase 3 Results of Aglatimagene Besadenovec at ASTRO 2026 Globe Newswire 8:05 AM

-- July 29, 2026 --

Candel Therapeutics to Present at Canaccord Genuity's 46th Annual Growth Conference in Boston Globe Newswire 8:05 AM

-- July 8, 2026 --

Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:05 PM

-- July 1, 2026 --

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:05 PM

-- June 30, 2026 --

Candel Therapeutics Announces Initiation of Global Pivotal Phase 3 AURORA Trial Evaluating Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors Globe Newswire 8:05 AM

-- June 25, 2026 --

Candel Therapeutics Appoints Mark Sims as Chief Commercial Officer Globe Newswire 8:05 AM

Market Data Delayed 15 Minutes